Allarity Therapeutics
ALLR
9 hedge funds and large institutions have $86.5K invested in Allarity Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
50% more funds holding
Funds holding: 6 → 9 (+3)
0.27% less ownership
Funds ownership: 2.36% → 2.08% (-0.27%)
29% less capital invested
Capital invested by funds: $122K → $86.5K (-$35.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$35.1K |
| 2 |
Morgan Stanley
New York
|
+$24.1K |
| 3 |
CCM
Corsair Capital Management
New York
|
+$20.7K |
| 4 |
Barclays
London,
United Kingdom
|
+$10.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$454 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$78.7K |
| 2 |
Goldman Sachs
New York
|
-$24.1K |
| 3 |
Citigroup
New York
|
-$14.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $31.8K | +$35.1K | +33,921 | New |
|
|
2
Morgan Stanley
New York
| $21.8K | +$24.1K | +23,311 | New |
|
|
CCM
3
Corsair Capital Management
New York
| $18.7K | +$20.7K | +20,000 | New |
|
|
4
Barclays
London,
United Kingdom
| $9.44K | +$10.4K | +10,078 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $4.41K | +$454 | +439 | +10% |
|
6
UBS Group
Zurich,
Switzerland
| $281 | +$310 | +300 | New |
|
7
Bank of America
Charlotte,
North Carolina
| $36 | +$17 | +16 | +73% |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $6 | +$7 | +7 | New |
|
|
DB
9
Danske Bank
Copenhagen K,
Denmark
| $1 | – | – | – |
|
|
SCM
10
Stonepine Capital Management
Bend,
Oregon
| – | -$78.7K | -67,289 | Closed |
|
|
11
Goldman Sachs
New York
| – | -$24.1K | -20,616 | Closed |
|
|
12
Citigroup
New York
| – | -$14.4K | -12,294 | Closed |
|
ALLR Hedge Fund Activity: Q1 2025 in Review
9 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q1 2025, worth a combined $86.5K — down 29% from $122K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ALLR positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $35.1K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $78.7K sold.
- 9 institutional investors held Allarity Therapeutics (ALLR) as of Q1 2025, up from 6 in Q4 2024.
- Funds reported $86.5K of Allarity Therapeutics stock for Q1 2025, down 29% quarter-over-quarter.
- 6 funds opened new Allarity Therapeutics positions in Q1 2025 and 3 closed out, a net change of +3 holders.
- The largest Allarity Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $35.1K added.
- The largest Allarity Therapeutics seller in Q1 2025 was Stonepine Capital Management, an estimated $78.7K sold.
Based on aggregated 13F filings for Q1 2025.